In this article, we will be taking a look at the 15 best biotech stocks to buy according to billionaires. Although biotech ...

There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.

H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.

Driving the consideration is the growing concern over power demand growth from data centers, which could double by 2029.

The Hong Kong University of Science and Technology (HKUST) and Shanghai Industrial Investment (Holdings) Co., Ltd. (SIIC) together announced the ...

Bluejay Therapeutics, a drug developer focused on serious viral and liver diseases, is considering a US initial public offering, according to people familiar with the matter.

Many experts — be they venture capitalists or private equity investors — shared their advice with biotech entrepreneurs ...

Hinge Health, Inc. targets a $326B market with innovative musculoskeletal care solutions. Click here to find out more about the upcoming HNGE stock IPO.

Market volatility makes listing a ‘monumental challenge.’ Meanwhile, limited partners are under pressure as distributions dry up.

Officers, beneficial owners, and other insiders have shelled out more than $10 million on each of these four biotech stocks ...

Public and private M&A are both key for Germany, but it is fair to say that private deals are still dominating the league ...

US IPO activity saw a meaningful recovery in 2024, with 38% more IPOs and 48% higher proceeds. 2025 may bring even more ...